Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
Recap: Gamida Cell Q2 Earnings
  Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers... 
Via Benzinga
Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
Via Benzinga
Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
Via Benzinga
Gamida Cell: Q4 Earnings Insights
Gamida Cell (NASDAQ:GMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff
Gamida Cell Ltd (NASDAQ: GMDA) will terminat 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gamida Cell: Q1 Earnings Insights
Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Gamida Cell reported in-line EPS of... 
Via Benzinga
Earnings Preview: Gamida Cell
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Gamida Cell will... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
Preview: Gamida Cell's Earnings
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Merck (MRK) Outperforms Industry, What's In Store For 2022?
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. 
Via Talk Markets
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US
Gamida Cell Ltd (NASDAQ: GMDA) has initiated the Biologics License Application (BLA)  
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 29.8% to $0.2550. Baudax Bio, last month, announced a $4.2 million registered direct offering. Vertical Aerospace Ltd. (NYSE... 
Via Benzinga
Hot Penny Stocks: What’s Moving VVOS, GMDA and SBEV Higher Today?
Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space. 
Via InvestorPlace
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion. Splash Beverage Group,... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.